← Leaderboards
Danielle Stanisic
Johns Hopkins University
$1,401,089
Attributed
$2,802,178
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $748.9K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,802,178 · 1
By mechanism
R01$2,802,178 · 1
Top collaborators
- Prakash Srinivasan4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Peter R Rapp$7,647,958
- Vernon Bruce Carruthers$18,903,624
- Timothy H. Moran$14,955,673
- Nirbhay Kumar$12,253,206
- Poonum S. Korpe$4,826,452
Others in their field
Other Rising Stars on “Efficacy Evaluation”
- Angee Greer · Ppd Development Lp$82,531,927
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Suma Babu · Massachusetts General Hospital$26,348,733
- Kevin Saunders · Duke University$18,106,404
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
Research focus
Efficacy EvaluationGenerationsDesignDrug ResistanceDoseAntigensCountryAdjuvantAntigenic DiversityApical MembraneAmino AcidsBindingBiological SexBloodAntibodiesCd4 Positive T LymphocytesCellsCellular ImmunityCessation Of LifeChildClinical DevelopmentClinical TrialsComplexGenetic Polymorphism
Grant awards (4)
Developing a multi-component vaccine harnessing potent antibody and cellular responses against the blood-stage of Plasmodium falciparum$697,101
R01 · FY2025 · AI
Developing a multi-component vaccine harnessing potent antibody and cellular responses against the blood-stage of Plasmodium falciparum$748,920
R01 · FY2024 · AI
Developing a multi-component vaccine harnessing potent antibody and cellular responses against the blood-stage of Plasmodium falciparum$672,371
R01 · FY2023 · AI
Developing a multi-component vaccine harnessing potent antibody and cellular responses against the blood-stage of Plasmodium falciparum$683,786
R01 · FY2022 · AI